Vaxcyte, Inc. PCVX

Vaxcyte's (PCVX) upcoming data readout for its investigational pneumococcal conjugate vaccine VAX-31

Vaxcyte (PCVX) has drawn fresh attention after recent trading left the share price at US$58.13, with short term performance mixed and longer term returns still materially positive for existing holders. Recent trading has cooled some of Vaxcyte’s earlier momentum, with the share price down over the past month but still showing a 90-day share price return of 11.87% and a 1-year total shareholder return of 73.68%, which points to strong longer term sentiment. Scan how Vaxcyte’s recent run...

On September 3, Vaxcyte (NASDAQ:PCVX) announced two new C-suite hires and moved up the date for its most important looming catalyst. The company said it now expects topline safety, tolerability and immunogenicity data from the VAX-31 adult Phase 3 OPUS-1 trial by the end of October, narrowing guidance that had previously pointed only to sometime […]

On August 5, Vaxcyte (NASDAQ:PCVX) reported second-quarter results that read less like a snapshot of today and more like a countdown to a verdict. The clinical-stage vaccine maker has no product on the market yet, but its three late-stage trials for its lead pneumococcal candidate are now fully enrolled, with the first major readout due […]

Luis Jodar, Ph.D., Former Pfizer Chief Medical Officer for Vaccines and Infectious Diseases with Extensive Leadership Experience Across Clinical Development and Medical Affairs for Pneumococcal Conjugate Vaccines Prevnar 13 and Prevnar 20, Joins Vaxcyte as Chief Medical Officer David McAvoy, J.D., Former Teva Chief Legal Officer, Joins Vaxcyte as Chief Legal Officer Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Pivotal Trial Expected by End of October 2026

SAN CARLOS, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in fireside chats and host one-on-one meetings at the following investor conferences: Wells Fargo 21st Annual Healthcare Conference, September 8-10, 2026: Fireside chat will take place on Tuesday, September 8 at 3:00 p.m. ET / 12:00 p.m. PT.Cantor Global Healthcare Conference, September 9-11, 2026: Fireside chat

Retail investors who spotted Seth Klarman buying Vaxcyte in May were already two months behind a trade Baupost had quietly begun unwinding. Understanding exactly what got lost in that gap changes how you should read every 13F going forward.

WESTON, Fla., August 11, 2026--ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the appointments of Jim Wassil, currently Chief Operating Officer at Vaxcyte; Suha Jhaveri, former Strategic Advisor at Cidara before its acquisition by Merck; and Bill Warren, former Global Head of Antigen Design at Sanofi Vaccines, as independent members of ILiAD’s Board of Directors. Th

Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half of 2027 Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Booster Dose of VAX-31 Infant Phase 2 Dose-Finding Study Expected Either Sequentially or Together by End of First Half of 2027 Company Initiated Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by

Vaxcyte Inc. (NASDAQ:PCVX) is one of the 8 Hidden Multibagger Stocks to Buy Now. On June 18, Mizuho Securities analyst Salim Syed reiterated a Buy rating on Vaxcyte Inc. (NASDAQ:PCVX) with a price target of $163. The firm’s price target reflects a significant 180% upside from current levels. Earlier on June 16, PCVX announced an […]

Vaxcyte, Inc. (NASDAQ:PCVX) is one of the most promising healthcare stocks according to Wall Street analysts. On June 2, Vaxcyte, Inc. (NASDAQ:PCVX) dosed the first participant in its Phase 1 first-in-human clinical trial of VAX-A1. VAX-A1 is the company’s experimental vaccine against Group A Streptococcus, or Group A Strep. The dosing marks Vaxcyte’s entry of […]

Vaxcyte Inc. (NASDAQ:PCVX) is one of the 10 best mid-cap stocks that could double your money. On June 3, Vaxcyte Inc. (NASDAQ:PCVX) announced that the first participant was dosed in the Phase 1, first-in-human study evaluating VAX-A1. This is the company’s investigational prophylactic vaccine candidate for the prevention of disease caused by Group A Streptococcus […]

Recently published Pneumonia Market Insights report includes a comprehensive understanding of current treatment practices, pneumonia emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].